X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Midatech Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 23, 2023
Details:
Under the terms of the agreement, the Company purchased all right, title and interest in the intellectual property owned by the Sellers related to their epidermal growth factor (EGF) platform, including CRES101.
Lead Product(s): CRES101
Therapeutic Area: Rare Diseases and Disorders Product Name: CRES101
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Cresence
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 16, 2022
Details:
Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.
Lead Product(s): Tomaralimab
Therapeutic Area: Neurology Product Name: NM-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Neuramedy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022
Details:
Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis’ xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 11, 2022
Details:
Oxyrane is developing enhanced enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs) using a proprietary, glyco-engineered yeast expression system for efficient targeting of enzymes to the lysosome.
Lead Product(s): Enzyme Replacement Therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oxyrane
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2021
Details:
The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.
Lead Product(s): Transcend-peptide
Therapeutic Area: Genetic Disease Product Name: xB3
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: CHIESI USA INC
Deal Size: $141.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement June 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
